Business Wire

Cofactor Genomics expands clinical use of OncoPrism, as their AI enabled RNA test achieves national clinical validation after predicting immunotherapy response in Lung Cancer ...

ST. LOUIS--(BUSINESS WIRE)--Cofactor Genomics, Inc., a clinical-stage company bridging the precision medicine gap by decoding RNA, announced today the validation and launch of OncoPrism ®-NSCLC, an ...
Business Wire

Cofactor Genomics Opens Enrollment for Non-small Cell Lung Cancer Study of OncoPrism Predictive Diagnostic Assay

SAN FRANCISCO--(BUSINESS WIRE)--Cofactor Genomics, the diagnostics company bridging the precision medicine gap, today announced commencement of a study of its OncoPrism™ assay in non-small cell lung ...
C&EN

Artificial cofactor system sustains central metabolism in bacteria

Many enzymes require cofactors such as nicotinamide adenosine dinucleotide (NAD +) or nicotinamide adenosine dinucleotide phosphate (NADP +) to shuttle electrons between reactions. Artificial redox ...
Pharmabiz

Cofactor Genomics begins patient enrolment in NSCLC study of OncoPrism predictive diagnostic assay

Cofactor Genomics, the diagnostics company bridging the precision medicine gap, announced commencement of a study of its OncoPrism assay in non-small cell lung cancer (NSCLC), the second indication ...
Yahoo Finance

Cofactor Genomics Publishes Clinical Validation of OncoPrism-HNSCC, a Test Leveraging Novel RNA Modeling Technology to Predict Response to Immunotherapy

ST. LOUIS, November 07, 2024--(BUSINESS WIRE)--Cofactor Genomics, Inc., a clinical-stage company bridging the precision medicine gap by decoding RNA, announced the publication of their PREDAPT ...